Webinar 1: Beyond The Bench: Transforming Cancer Diagnosis and Treatment Decision Making Through Liquid Biopsies

Liquid biopsies are revolutionising how we detect, monitor, and manage cancer, offering a fast, non-invasive view into tumour biology at the molecular level. Yet many patients are still diagnosed too late, receive ineffective treatments, or relapse due to minimal residual disease (MRD) that traditional methods miss.

How can we fully harness the potential of liquid biopsies to detect cancer earlier, guide better treatment decisions, and deliver truly personalised care?

Register for Liquid Biopsy Online to:

• Discover how liquid biopsies are improving the management of solid tumours.
• Explore real-world applications of circulating tumour DNA (ctDNA) and circulating tumour cells (CTCs), focusing on approaching the challenges hindering their routine clinical implementation.
• Hear about the different ways liquid biopsies are guiding treatment decision-making across multiple cancer types.
• Understand the role of liquid biopsies in MRD detection and resistance monitoring.
• Hear how leading researchers integrate liquid biopsies into clinical practice to improve patient outcomes.

Webinar 1: Beyond The Bench: Transforming Cancer Diagnosis and Treatment Decision Making Through Liquid Biopsies

Thursday 22nd May, 3pm BST/ 4pm CEST/ 10am EDT

Sponsored by Asuragen

This webinar will demonstrate the strength of using liquid biopsies to detect molecular relapse early, optimise rare variant detection, and improve clinical workflows for better patient outcomes.

Talk 1: Liquid Biopsy in Solid Tumours

Umberto Malapelle, Associate Professor in the School of Medicine, University of Naples Federico II

Talk 2: Small But Mighty: Leveraging Exosomes in Liquid Biopsy for Highly Sensitive qPCR Variant Detection

Kevin Kelnar, Senior Manager R&D, Research & Development, Asuragen

Talk 3: Advancing Liquid Biopsy Technologies: High-Volume CTC Detection for Precision Medicine

Nikolas Stoecklein, Professor, University Hospital Dusseldorf

Talk 4: Utility of ctDNA in Sarcoma: Challenges and Promising Advances

Brittany Siontis, Assistant Professor & Medical Oncologist, Mayo Clinic

Upcoming webinars in this series:

Webinar 2: From Detection to Decision: Liquid Biopsies for Treatment Monitoring

Thursday 29th May, 3pm BST/ 4pm CEST/ 10am EDT

Sponsored by QIAGEN

Join us to explore the evolving role of liquid biopsies in cancer care, featuring cutting-edge advances in cfDNA multi-omics, clinical applications in metastatic breast cancer and dynamic risk stratification.

Talk 1: Cracking the Code of cfDNA: Integrating Fragmentomics into Liquid Biopsies

Alexandra Clipson, Deputy Team Leader, Cancer Research UK

Talk 2: Liquid Biopsies to Guide Treatment Decisions for Metastatic Breast Cancer

Jenna Canzoniero, Assistant Professor, Johns Hopkins University

Talk 3: Dynamic Risk Stratification using Circulating HPV DNA

Scott Bratman, Associate Professor, University of Toronto

Webinar 3: Expanding Liquid Biopsy Applications in Clinical Care

Thursday 5th June, 3pm BST/ 4pm CEST/ 10am EDT

What’s next for liquid biopsies? This webinar will explore the use of multi-cancer early detection (MCED), epigenomic profiling, and multi-modal integration to improve the standard of cancer care.

Talk 1: Determination of Tumour PSMA Expression and Lutetium-PSMA Response in Men with Prostate Cancer Using a Novel Epigenomic Liquid Biopsy Platform

Jacob Berchuck, Assistant Professor, Emory University

Talk 2: The Clinical Potential of Liquid Biopsies for Effective Treatment Selection and Resistance Monitoring in Metastatic Cancers

Hai Tran, Associate Professor, MD Anderson Cancer Center

Talk 3: Boosting Liquid Biopsies using Multi-Modal Integration

Florent Mouliere, Team Leader, Cancer Research UK